Literature DB >> 27284483

Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises.

Lin Mei1, Wei Du1, Wen Wee Ma1.   

Abstract

Pancreatic cancer is a highly lethal disease. Conventional therapeutics targeting pancreas cancer cell compartment using cytotoxics improved patient survival but at the expense of significant toxicity. Microscopically, the tumor is characterized by thick desmoplastic stroma that surrounds islands of pancreatic cancer cells. The tumor microenvironment has been found to play important roles in carcinogenesis, the development of drug resistance, and mediating immunosuppression. The understanding the tumor-stromal interaction has led to the development of novel therapeutic approaches. Here, we review the strategies that are currently in (or, near to) clinical evaluation and the underlying preclinical rationales.

Entities:  

Keywords:  Pancreatic cancer; cancer-associated fibroblast (CAF); clinical trials; pancreatic adenocarcinoma; stroma

Year:  2016        PMID: 27284483      PMCID: PMC4880763          DOI: 10.21037/jgo.2016.03.03

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  48 in total

Review 1.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

2.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

3.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

Review 5.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies.

Authors:  Agnieszka Anna Rucki; Lei Zheng
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Pancreatic cancer stroma: friend or foe?

Authors:  Jesse Gore; Murray Korc
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

7.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 8.  The integrin-extracellular matrix axis in pancreatic cancer.

Authors:  John J Grzesiak; Jason C Ho; Abdool R Moossa; Michael Bouvet
Journal:  Pancreas       Date:  2007-11       Impact factor: 3.327

9.  Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Authors:  Gary Middleton; Paul Silcocks; Trevor Cox; Juan Valle; Jonathan Wadsley; David Propper; Fareeda Coxon; Paul Ross; Srinivasan Madhusudan; Tom Roques; David Cunningham; Stephen Falk; Nick Wadd; Mark Harrison; Pippa Corrie; Tim Iveson; Angus Robinson; Karen McAdam; Martin Eatock; Jeff Evans; Caroline Archer; Tamas Hickish; Angel Garcia-Alonso; Marianne Nicolson; William Steward; Alan Anthoney; William Greenhalf; Victoria Shaw; Eithne Costello; Dean Naisbitt; Charlotte Rawcliffe; Gemma Nanson; John Neoptolemos
Journal:  Lancet Oncol       Date:  2014-06-19       Impact factor: 41.316

10.  Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.

Authors:  Surabhi Dangi-Garimella; Vaibhav Sahai; Kazumi Ebine; Krishan Kumar; Hidayatullah G Munshi
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more
  20 in total

1.  Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model.

Authors:  Junjie Gu; Zhe Li; Jianfeng Zhou; Zhao Sun; Chunmei Bai
Journal:  Oncol Lett       Date:  2019-06-14       Impact factor: 2.967

2.  Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.

Authors:  Andrew E Shouksmith; Fenil Shah; Michelle L Grimard; Justyna M Gawel; Yasir S Raouf; Mulu Geletu; Angelika Berger-Becvar; Elvin D de Araujo; H Artee Luchman; William L Heaton; David Bakhshinyan; Ashley A Adile; Chitra Venugopal; Thomas O'Hare; Michael W Deininger; Sheila K Singh; Stephen F Konieczny; Samuel Weiss; Melissa L Fishel; Patrick T Gunning
Journal:  J Med Chem       Date:  2019-03-06       Impact factor: 7.446

3.  Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?

Authors:  Rossana Berardi; Alessandro Bittoni
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

Authors:  Anteneh A Tesfaye; Mandana Kamgar; Asfar Azmi; Philip A Philip
Journal:  Expert Rev Anticancer Ther       Date:  2017-12-19       Impact factor: 4.512

5.  PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker.

Authors:  Jérémy Nigri; Meritxell Gironella; Christian Bressy; Elena Vila-Navarro; Julie Roques; Sophie Lac; Caroline Bontemps; Coraline Kozaczyk; Jérôme Cros; Daniel Pietrasz; Raphaël Maréchal; Jean-Luc Van Laethem; Juan Iovanna; Jean-Baptiste Bachet; Emma Folch-Puy; Richard Tomasini
Journal:  Cell Mol Life Sci       Date:  2017-06-27       Impact factor: 9.261

Review 6.  Strategies for Increasing Pancreatic Tumor Immunogenicity.

Authors:  Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

7.  Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.

Authors:  Abdel Nasser Hosein; Huocong Huang; Zhaoning Wang; Kamalpreet Parmar; Wenting Du; Jonathan Huang; Anirban Maitra; Eric Olson; Udit Verma; Rolf A Brekken
Journal:  JCI Insight       Date:  2019-07-23

8.  Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium.

Authors:  Wenzhi Tan; Mai Thi-Quynh Duong; Chaohui Zuo; Yeshan Qin; Ying Zhang; Yanxia Guo; Yeongjin Hong; Jin Hai Zheng; Jung-Joon Min
Journal:  Mol Ther       Date:  2021-08-14       Impact factor: 11.454

Review 9.  Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.

Authors:  Elaine Tan; Bassel El-Rayes
Journal:  J Gastrointest Cancer       Date:  2019-03

10.  CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma.

Authors:  Xiaohui Zhang; Lisa Detering; Deborah Sultan; Hannah Luehmann; Lin Li; Gyu Seong Heo; Xiuli Zhang; Lanlan Lou; Patrick M Grierson; Suellen Greco; Marianna Ruzinova; Richard Laforest; Farrokh Dehdashti; Kian-Huat Lim; Yongjian Liu
Journal:  ACS Nano       Date:  2021-01-06       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.